Krilogy Financial LLC Invests $2.51 Million in Repligen Corporation $RGEN

Key Points

• Krilogy Financial LLC has invested approximately $2.51 million in Repligen Corporation, acquiring 20,201 shares of the biotechnology company's stock.
• Following a lackluster earnings report, Repligen's stock has been given mixed ratings from analysts, with price targets ranging from $135.00 to $205.00.
• 97.64% of Repligen's stock is owned by hedge funds and institutional investors, highlighting the company's strong institutional interest.

Krilogy Financial LLC bought a new position in Repligen Corporation (NASDAQ:RGEN - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 20,201 shares of the biotechnology company's stock, valued at approximately $2,513,000.

A number of other hedge funds also recently made changes to their positions in RGEN. Quantinno Capital Management LP lifted its position in shares of Repligen by 80.0% in the fourth quarter. Quantinno Capital Management LP now owns 3,523 shares of the biotechnology company's stock worth $507,000 after buying an additional 1,566 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of Repligen by 7.4% in the fourth quarter. ProShare Advisors LLC now owns 2,438 shares of the biotechnology company's stock worth $351,000 after buying an additional 167 shares in the last quarter. Raiffeisen Bank International AG purchased a new stake in shares of Repligen in the fourth quarter worth about $29,000. Two Sigma Advisers LP lifted its position in shares of Repligen by 6.7% in the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company's stock worth $19,403,000 after buying an additional 8,500 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Repligen by 12.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company's stock worth $33,875,000 after buying an additional 26,733 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Repligen

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares in the company, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is currently owned by insiders.

Repligen Trading Up 0.2%

Shares of NASDAQ RGEN opened at $113.74 on Tuesday. The stock has a market capitalization of $6.40 billion, a P/E ratio of -454.94, a PEG ratio of 2.09 and a beta of 1.07. The business's 50 day moving average is $120.52 and its two-hundred day moving average is $127.26. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same period in the prior year, the business posted $0.40 earnings per share. Repligen's revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on RGEN shares. Jefferies Financial Group decreased their target price on Repligen from $145.00 to $135.00 and set a "hold" rating on the stock in a research report on Friday. Royal Bank Of Canada reiterated an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research report on Tuesday, September 2nd. Stephens raised Repligen to an "overweight" rating and set a $160.00 price objective on the stock in a research note on Tuesday, July 22nd. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price objective on the stock. Finally, Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Repligen presently has an average rating of "Moderate Buy" and a consensus target price of $166.67.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.